Nevertheless, clinical practice may be guided by recommendations developed for the management of bone health in breast cancer patients treated with aromatase inhibitors, given the similar pathophysiological mechanisms underlying bone loss in both settings [54,55]. The gene discussed is CYP19A1; the disease is breast cancer.